Healthcare technology company Medtronic plc (NYSE:MDT) said Tuesday that the U.S. Food and Drug Administration has cleared its Hugo robotic-assisted surgery, or RAS, system for general surgery, opening access to roughly 3.5 million annual U.S. procedures.
Expanding Access To Soft-Tissue Procedures
The FDA clearance covers all upper abdominal general surgeries, including cholecystectomy, Roux-en-Y gastric bypass, ventral hernia, and small bowel resection, the company said.
Regulators also cleared lower abdominal procedures, specifically appendectomy and inguinal hernia repairs.
The operations represent more than half of all soft-tissue surgeries that surgeons perform each year in the United States.
Strong Global Procedure Growth
The decision expands the Hugo RAS system beyond urology in U.S. hospitals and builds on Medtronic’s half-century presence in open and laparoscopic surgery.
Worldwide, Hugo RAS procedure volume has been growing at more than twice the pace of the broader robotic surgery market, tracking to exceed 50,000 procedures by the end of Medtronic’s fiscal year.
Outside the U.S., general surgery already leads Hugo RAS growth ahead of urology and gynecology.
Modular Design And Trusted Surgical Tools
The system’s modular setup lets surgical teams deploy only necessary robotic arms and position them around patient anatomy, while an open console keeps surgeons connected to operating room staff.
Teams can also pair the platform with the LigaSure RAS Maryland instrument, bringing vessel-sealing technology from over 45 million procedures into robotic surgery.
MDT Price Action: Medtronic shares were down 0.06% at $102.82 on Tuesday, according to Benzinga Pro data.
Image via Shutterstock
© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.





